Most type II ovarian carcinomas (96%) have TP53 mutation [2,3] and approximately 50% of germline high-grade serous ovarian cancers (HGSOCs) carry an alteration in homologous recombination (HR) pathway genes, most commonly in breast cancer (BRCA) gene 1/2 [4]. Here, TP53 is linked to ovarian carcinoma.